These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

Benzinga

2025/05/07

CRISPR Therapeutics AG (NASDAQ:CRSP) posted a loss for the first quarter on Tuesday.

The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share. The company posted sales of $865,000.

“CRISPR Therapeutics remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Additionally, we are pleased with the continued progress of Casgevy and the broader pipeline, and we look forward to sharing further clinical updates in the months ahead.”

CRISPR Therapeutics shares dipped 11.9% to close at $33.16 on Tuesday.

These analysts made changes to their price targets on CRISPR Therapeutics following earnings announcement.

Chardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from $84 to $82.
Needham analyst Gil Blum maintained the stock with a Buy and lowered the price target from $84 to $81.

Considering buying CRSP stock? Here’s what analysts think:

Read This Next:

Top 2 Energy Stocks That Are Ticking Portfolio Bombs

Photo via Shutterstock

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2533987747"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533987747\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533987747?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533987747","market":"us","top_or_hot":-1,"title":"These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/CRSP\">CRISPR Therapeutics AG</a></strong> (NASDAQ:CRSP) posted a loss for the first quarter on Tuesday.</p>\n<p>The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share. The company posted sales of $865,000.</p>\n<p>“CRISPR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Additionally, we are pleased with the continued progress of Casgevy and the broader pipeline, and we look forward to sharing further clinical updates in the months ahead.”</p>\n<p>CRISPR Therapeutics shares dipped 11.9% to close at $33.16 on Tuesday.</p>\n<p>These analysts made changes to their price targets on CRISPR Therapeutics following earnings announcement.</p>\n<ul>\n<li>Chardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from $84 to $82.</li>\n<li>Needham analyst Gil Blum maintained the stock with a Buy and lowered the price target from $84 to $81.</li>\n</ul>\n<p><strong>Considering buying CRSP stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"619\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-1024x619.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-1024x619.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-300x181.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-768x464.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26.png 1095w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Energy Stocks That Are Ticking Portfolio Bombs</strong> </li>\n</ul>\n<p>Photo via Shutterstock</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2025-05-07 20:39</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/CRSP\">CRISPR Therapeutics AG</a></strong> (NASDAQ:CRSP) posted a loss for the first quarter on Tuesday.</p>\n<p>The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share. The company posted sales of $865,000.</p>\n<p>“CRISPR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “Additionally, we are pleased with the continued progress of Casgevy and the broader pipeline, and we look forward to sharing further clinical updates in the months ahead.”</p>\n<p>CRISPR Therapeutics shares dipped 11.9% to close at $33.16 on Tuesday.</p>\n<p>These analysts made changes to their price targets on CRISPR Therapeutics following earnings announcement.</p>\n<ul>\n<li>Chardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from $84 to $82.</li>\n<li>Needham analyst Gil Blum maintained the stock with a Buy and lowered the price target from $84 to $81.</li>\n</ul>\n<p><strong>Considering buying CRSP stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"619\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-1024x619.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-1024x619.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-300x181.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26-768x464.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07083810/image-2-26.png 1095w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Top 2 Energy Stocks That Are Ticking Portfolio Bombs</strong> </li>\n</ul>\n<p>Photo via Shutterstock</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/25/05/45250973/these-analysts-slash-their-forecasts-on-crispr-therapeutics-following-q1-results","article_id":"2533987747","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533987747","pubTimestamp":1746621581,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4611":"AI医疗","CRSP":"CRISPR Therapeutics AG","BK4585":"ETF&股票定投概念","BK4007":"制药","BK4588":"碎股","LENZ":"Therapeutics","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4556":"基因编辑","LU1861558580.USD":"日兴方舟颠覆性创新基金B"},"translate_title":"这些分析师在第一季度业绩公布后大幅下调了对CRISPR Therapeutics的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1,"LENZ":1},"content_text":"CRISPR Therapeutics AG (NASDAQ:CRSP) posted a loss for the first quarter on Tuesday.\nThe company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share. The company posted sales of $865,000.\n「CRISPR Therapeutics remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease,」 said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. 「Additionally, we are pleased with the continued progress of Casgevy and the broader pipeline, and we look forward to sharing further clinical updates in the months ahead.」\nCRISPR Therapeutics shares dipped 11.9% to close at $33.16 on Tuesday.\nThese analysts made changes to their price targets on CRISPR Therapeutics following earnings announcement.\n\nChardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from $84 to $82.\nNeedham analyst Gil Blum maintained the stock with a Buy and lowered the price target from $84 to $81.\n\nConsidering buying CRSP stock? Here’s what analysts think: \n\nRead This Next: \n\nTop 2 Energy Stocks That Are Ticking Portfolio Bombs \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}